Blue Genes Successfully Completes SOC 2 Audit
January 19, 2026 • Press Releases
Phoenix, AZ, January 16, 2026 — Blue Genes (https://bluegeneslab.com), a personalized medicine company focused on pharmacogenetic (PGx) testing and genetic insights to support safer, more effective medication decisions, today announced the successful completion of its SOC 2 Type II examination as of January 16, 2025.
BlueGenesLab Expands Genetic Panel to Include Three New GLP-1–Related Genes
September 08, 2025 • Press Releases
SCOTTSDALE, Ariz., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BlueGenesLab, a precision genomics company headquartered in Scottsdale, Arizona, today announced the addition of three genes to its clinical testing panel that influence GLP‑1 (glucagon‑like peptide‑1) biology. The expanded panel aims to improve personalized treatment strategies for metabolic conditions such as type 2 diabetes, obesity, and related cardiometabolic risks by providing clinicians and patients with a deeper genetic view of pathways that regulate GLP‑1 signaling, secretion, and response.
